KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Intangibles (2016 - 2022)

Historic Intangibles for Ionis Pharmaceuticals (IONS) over the last 14 years, with Q3 2022 value amounting to $29.6 million.

  • Ionis Pharmaceuticals' Intangibles fell 144.15% to $29.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $29.6 million, marking a year-over-year decrease of 144.15%. This contributed to the annual value of $29.0 million for FY2021, which is 382.29% up from last year.
  • As of Q3 2022, Ionis Pharmaceuticals' Intangibles stood at $29.6 million, which was down 144.15% from $29.1 million recorded in Q2 2022.
  • Ionis Pharmaceuticals' 5-year Intangibles high stood at $30.0 million for Q3 2021, and its period low was $22.9 million during Q1 2018.
  • Over the past 5 years, Ionis Pharmaceuticals' median Intangibles value was $27.7 million (recorded in 2020), while the average stood at $27.1 million.
  • In the last 5 years, Ionis Pharmaceuticals' Intangibles soared by 1231.11% in 2019 and then plummeted by 144.15% in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Intangibles stood at $24.0 million in 2018, then grew by 6.83% to $25.7 million in 2019, then increased by 8.81% to $27.9 million in 2020, then grew by 3.82% to $29.0 million in 2021, then grew by 2.07% to $29.6 million in 2022.
  • Its last three reported values are $29.6 million in Q3 2022, $29.1 million for Q2 2022, and $29.3 million during Q1 2022.